Filtered By:
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 18765 results found since Jan 2013.
Efficacy and Safety of Omalizumab Updosing in Chronic Urticaria: A Retrospective Study
Skinmed. 2023 Aug 28;21(3):170-175. eCollection 2023.ABSTRACTOmalizumab is an effective and safe treatment option with licensed doses in patients with chronic spontaneous urticaria (CSU); however, some patients are not responsive to licensed doses and require updosing. As studies concerning updosing were insufficient, the present study evaluated the effectiveness and safety of omalizumab updosing (300 mg every 2 weeks) in CSU patients. Data of CSU patients treated with omalizumab were analyzed retrospectively. As an outcome measure, physician assessment of treatment response (complete response [CR], partial response, and u...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Fatma Asli Hapa Fatma Elif Y ıldırım Source Type: research
Psori Silk in Mild to Moderate Psoriasis: A Randomized Phase I-II Trial Study
Skinmed. 2023 Aug 28;21(3):166-169. eCollection 2023.ABSTRACTIn patients with mild to moderate psoriasis, topical corticosteroids are usually the first-line of treatment; however, they are not suitable for long-term use. The purpose of this study was to assess the efficacy and safety of a multi-fruit-and-vegetable compound, Psori Silk, in the treatment of patients with psoriasis. This was a randomized double-blind trial comprising 12 weeks of treatment with Psori Silk versus a vehicle, and a 4-week follow-up. The primary endpoint was 50% reduction in the modified Psoriasis Area and Severity Index (MPASI 50) score at week 1...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Felix Pavlotsky Meir Babaev Aviv Barzilai Source Type: research
Efficacy and Safety of Omalizumab Updosing in Chronic Urticaria: A Retrospective Study
Skinmed. 2023 Aug 28;21(3):170-175. eCollection 2023.ABSTRACTOmalizumab is an effective and safe treatment option with licensed doses in patients with chronic spontaneous urticaria (CSU); however, some patients are not responsive to licensed doses and require updosing. As studies concerning updosing were insufficient, the present study evaluated the effectiveness and safety of omalizumab updosing (300 mg every 2 weeks) in CSU patients. Data of CSU patients treated with omalizumab were analyzed retrospectively. As an outcome measure, physician assessment of treatment response (complete response [CR], partial response, and u...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Fatma Asli Hapa Fatma Elif Y ıldırım Source Type: research
Psori Silk in Mild to Moderate Psoriasis: A Randomized Phase I-II Trial Study
Skinmed. 2023 Aug 28;21(3):166-169. eCollection 2023.ABSTRACTIn patients with mild to moderate psoriasis, topical corticosteroids are usually the first-line of treatment; however, they are not suitable for long-term use. The purpose of this study was to assess the efficacy and safety of a multi-fruit-and-vegetable compound, Psori Silk, in the treatment of patients with psoriasis. This was a randomized double-blind trial comprising 12 weeks of treatment with Psori Silk versus a vehicle, and a 4-week follow-up. The primary endpoint was 50% reduction in the modified Psoriasis Area and Severity Index (MPASI 50) score at week 1...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Felix Pavlotsky Meir Babaev Aviv Barzilai Source Type: research
A Boy Safely Treated with Tyrosine Kinase Inhibitors for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Osteolysis
Acta Med Okayama. 2023 Aug;77(4):439-442. doi: 10.18926/AMO/65757.ABSTRACTA three-year-old boy with Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ALL) presented with an osteolytic lesion in his right upper arm. Tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib are an essential component throughout the course of treatment for Ph+ALL. However, TKIs are reported to affect the bone metabolism. In the treatment course of the current patient, the osteolytic lesion quickly improved despite the continuous use of TKIs, even during the concomitant use of corticosteroids. This sugge...
Source: Acta Med Okayama - August 27, 2023 Category: Universities & Medical Training Authors: Takahiro Shiwaku Hisashi Ishida Yasuhisa Tatebe Kosuke Tamefusa Motoharu Ochi Kaori Fujiwara Toshihide Kubo Eiji Nakata Kana Washio Hirokazu Tsukahara Source Type: research
Efficacy and Safety of Omalizumab Updosing in Chronic Urticaria: A Retrospective Study
Skinmed. 2023 Aug 28;21(3):170-175. eCollection 2023.ABSTRACTOmalizumab is an effective and safe treatment option with licensed doses in patients with chronic spontaneous urticaria (CSU); however, some patients are not responsive to licensed doses and require updosing. As studies concerning updosing were insufficient, the present study evaluated the effectiveness and safety of omalizumab updosing (300 mg every 2 weeks) in CSU patients. Data of CSU patients treated with omalizumab were analyzed retrospectively. As an outcome measure, physician assessment of treatment response (complete response [CR], partial response, and u...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Fatma Asli Hapa Fatma Elif Y ıldırım Source Type: research
Psori Silk in Mild to Moderate Psoriasis: A Randomized Phase I-II Trial Study
Skinmed. 2023 Aug 28;21(3):166-169. eCollection 2023.ABSTRACTIn patients with mild to moderate psoriasis, topical corticosteroids are usually the first-line of treatment; however, they are not suitable for long-term use. The purpose of this study was to assess the efficacy and safety of a multi-fruit-and-vegetable compound, Psori Silk, in the treatment of patients with psoriasis. This was a randomized double-blind trial comprising 12 weeks of treatment with Psori Silk versus a vehicle, and a 4-week follow-up. The primary endpoint was 50% reduction in the modified Psoriasis Area and Severity Index (MPASI 50) score at week 1...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Felix Pavlotsky Meir Babaev Aviv Barzilai Source Type: research
Efficacy and Safety of Omalizumab Updosing in Chronic Urticaria: A Retrospective Study
Skinmed. 2023 Aug 28;21(3):170-175. eCollection 2023.ABSTRACTOmalizumab is an effective and safe treatment option with licensed doses in patients with chronic spontaneous urticaria (CSU); however, some patients are not responsive to licensed doses and require updosing. As studies concerning updosing were insufficient, the present study evaluated the effectiveness and safety of omalizumab updosing (300 mg every 2 weeks) in CSU patients. Data of CSU patients treated with omalizumab were analyzed retrospectively. As an outcome measure, physician assessment of treatment response (complete response [CR], partial response, and u...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Fatma Asli Hapa Fatma Elif Y ıldırım Source Type: research
A Boy Safely Treated with Tyrosine Kinase Inhibitors for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Osteolysis
Acta Med Okayama. 2023 Aug;77(4):439-442. doi: 10.18926/AMO/65757.ABSTRACTA three-year-old boy with Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ALL) presented with an osteolytic lesion in his right upper arm. Tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib are an essential component throughout the course of treatment for Ph+ALL. However, TKIs are reported to affect the bone metabolism. In the treatment course of the current patient, the osteolytic lesion quickly improved despite the continuous use of TKIs, even during the concomitant use of corticosteroids. This sugge...
Source: Acta Med Okayama - August 27, 2023 Category: Universities & Medical Training Authors: Takahiro Shiwaku Hisashi Ishida Yasuhisa Tatebe Kosuke Tamefusa Motoharu Ochi Kaori Fujiwara Toshihide Kubo Eiji Nakata Kana Washio Hirokazu Tsukahara Source Type: research
Efficacy and Safety of Omalizumab Updosing in Chronic Urticaria: A Retrospective Study
Skinmed. 2023 Aug 28;21(3):170-175. eCollection 2023.ABSTRACTOmalizumab is an effective and safe treatment option with licensed doses in patients with chronic spontaneous urticaria (CSU); however, some patients are not responsive to licensed doses and require updosing. As studies concerning updosing were insufficient, the present study evaluated the effectiveness and safety of omalizumab updosing (300 mg every 2 weeks) in CSU patients. Data of CSU patients treated with omalizumab were analyzed retrospectively. As an outcome measure, physician assessment of treatment response (complete response [CR], partial response, and u...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Fatma Asli Hapa Fatma Elif Y ıldırım Source Type: research
Psori Silk in Mild to Moderate Psoriasis: A Randomized Phase I-II Trial Study
Skinmed. 2023 Aug 28;21(3):166-169. eCollection 2023.ABSTRACTIn patients with mild to moderate psoriasis, topical corticosteroids are usually the first-line of treatment; however, they are not suitable for long-term use. The purpose of this study was to assess the efficacy and safety of a multi-fruit-and-vegetable compound, Psori Silk, in the treatment of patients with psoriasis. This was a randomized double-blind trial comprising 12 weeks of treatment with Psori Silk versus a vehicle, and a 4-week follow-up. The primary endpoint was 50% reduction in the modified Psoriasis Area and Severity Index (MPASI 50) score at week 1...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Felix Pavlotsky Meir Babaev Aviv Barzilai Source Type: research
